Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 6
2004 8
2005 10
2006 17
2007 9
2008 9
2009 5
2010 10
2011 16
2012 20
2013 15
2014 18
2015 19
2016 18
2017 27
2018 34
2019 45
2020 47
2021 35
2022 21
2023 17
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

350 results

Results by year

Filters applied: . Clear all
Page 1
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). Elad S, et al. Cancer. 2020 Oct 1;126(19):4423-4431. doi: 10.1002/cncr.33100. Epub 2020 Jul 28. Cancer. 2020. PMID: 32786044 Free PMC article.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Mori T. Mori T. Rinsho Ketsueki. 2018;59(5):495. doi: 10.11406/rinketsu.59.495. Rinsho Ketsueki. 2018. PMID: 29877237 Japanese. No abstract available.
Small-molecule ambipolar transistors.
Higashino T, Mori T. Higashino T, et al. Among authors: mori t. Phys Chem Chem Phys. 2022 May 4;24(17):9770-9806. doi: 10.1039/d1cp05799e. Phys Chem Chem Phys. 2022. PMID: 35420607 Review.
Mori T. Mori T. Rinsho Ketsueki. 2021;62(6):592. doi: 10.11406/rinketsu.62.592. Rinsho Ketsueki. 2021. PMID: 34219085 Japanese. No abstract available.
[Post-transplant infectious diseases].
Mori T. Mori T. Rinsho Ketsueki. 2014 Oct;55(10):2136-41. Rinsho Ketsueki. 2014. PMID: 25297780 Review. Japanese. No abstract available.
[Malignant paraganglioma mimicking multiple myeloma].
Nagao T, Bando K, Iura A, Kakuta R, Kano Y, Ikeda S, Nogami A, Tanaka Y, Kirimura S, Mori T. Nagao T, et al. Among authors: mori t. Rinsho Ketsueki. 2022;63(10):1373-1378. doi: 10.11406/rinketsu.63.1373. Rinsho Ketsueki. 2022. PMID: 36351642 Japanese.
Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer.
Noji R, Tohyama K, Kugimoto T, Kuroshima T, Hirai H, Tomioka H, Michi Y, Tasaki A, Ohno K, Ariizumi Y, Onishi I, Suenaga M, Mori T, Okamoto R, Yoshimura R, Miura M, Asakage T, Miyake S, Ikeda S, Harada H, Kano Y. Noji R, et al. Among authors: mori t. Cancers (Basel). 2022 Jul 18;14(14):3476. doi: 10.3390/cancers14143476. Cancers (Basel). 2022. PMID: 35884537 Free PMC article.
350 results